Tejas Savant
Stock Analyst at Morgan Stanley
(2.17)
# 2,692
Out of 4,711 analysts
213
Total ratings
39.86%
Success rate
-5.21%
Average return
Main Sectors:
Stocks Rated by Tejas Savant
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| STVN Stevanato Group | Assumes: Equal-Weight | $24 → $23 | $20.56 | +11.87% | 1 | Dec 3, 2024 | |
| GRAL GRAIL | Initiates: Equal-Weight | $16 | $18.35 | -12.81% | 1 | Nov 27, 2024 | |
| VCYT Veracyte | Maintains: Underweight | $26 → $28 | $40.89 | -31.52% | 13 | Nov 18, 2024 | |
| MYGN Myriad Genetics | Maintains: Equal-Weight | $32 → $21 | $13.36 | +57.19% | 2 | Nov 18, 2024 | |
| NTRA Natera | Maintains: Overweight | $132 → $176 | $161.88 | +8.72% | 12 | Nov 14, 2024 | |
| ILMN Illumina | Reinstates: Equal-Weight | $156 | $136.02 | +14.69% | 5 | Nov 12, 2024 | |
| IQV IQVIA Holdings | Maintains: Overweight | $280 → $265 | $197.27 | +34.33% | 10 | Nov 4, 2024 | |
| TMO Thermo Fisher | Maintains: Overweight | $655 → $680 | $524.05 | +29.76% | 12 | Sep 20, 2024 | |
| TXG 10x Genomics | Maintains: Overweight | $50 → $46 | $14.04 | +227.64% | 11 | Aug 13, 2024 | |
| MRVI Maravai LifeSciences Holdings | Downgrades: Equal-Weight | $11 → $10 | $5.37 | +86.22% | 12 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $4 → $2 | $1.97 | +1.52% | 13 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $4 → $3 | $2.49 | +20.48% | 10 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $29 | $21.21 | +36.73% | 15 | Jul 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $44 | $35.54 | +23.80% | 1 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $80 → $40 | $10.08 | +296.83% | 2 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $86 → $82 | $71.65 | +14.45% | 7 | Nov 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $8 → $7 | $6.32 | +10.76% | 8 | Nov 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $16 → $17 | $16.41 | +3.60% | 12 | Nov 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $13 → $10 | $6.39 | +56.49% | 11 | Oct 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $16 | $7.86 | +103.56% | 1 | Aug 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $6 | $1.76 | +240.91% | 3 | Aug 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $10 | $3.26 | +206.75% | 8 | May 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $2.75 | $0.90 | +205.56% | 6 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $5 | $5.75 | -13.04% | 12 | Feb 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $10 | $2.31 | +332.90% | 10 | Feb 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $80 → $73 | $31.67 | +130.50% | 9 | Feb 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $350 → $250 | $185.77 | +34.58% | 1 | Aug 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $5 | $1.57 | +218.47% | 5 | May 12, 2022 |
Stevanato Group
Dec 3, 2024
Assumes: Equal-Weight
Price Target: $24 → $23
Current: $20.56
Upside: +11.87%
GRAIL
Nov 27, 2024
Initiates: Equal-Weight
Price Target: $16
Current: $18.35
Upside: -12.81%
Veracyte
Nov 18, 2024
Maintains: Underweight
Price Target: $26 → $28
Current: $40.89
Upside: -31.52%
Myriad Genetics
Nov 18, 2024
Maintains: Equal-Weight
Price Target: $32 → $21
Current: $13.36
Upside: +57.19%
Natera
Nov 14, 2024
Maintains: Overweight
Price Target: $132 → $176
Current: $161.88
Upside: +8.72%
Illumina
Nov 12, 2024
Reinstates: Equal-Weight
Price Target: $156
Current: $136.02
Upside: +14.69%
IQVIA Holdings
Nov 4, 2024
Maintains: Overweight
Price Target: $280 → $265
Current: $197.27
Upside: +34.33%
Thermo Fisher
Sep 20, 2024
Maintains: Overweight
Price Target: $655 → $680
Current: $524.05
Upside: +29.76%
10x Genomics
Aug 13, 2024
Maintains: Overweight
Price Target: $50 → $46
Current: $14.04
Upside: +227.64%
Maravai LifeSciences Holdings
Aug 13, 2024
Downgrades: Equal-Weight
Price Target: $11 → $10
Current: $5.37
Upside: +86.22%
Aug 12, 2024
Maintains: Equal-Weight
Price Target: $4 → $2
Current: $1.97
Upside: +1.52%
Aug 6, 2024
Downgrades: Equal-Weight
Price Target: $4 → $3
Current: $2.49
Upside: +20.48%
Jul 29, 2024
Maintains: Overweight
Price Target: $28 → $29
Current: $21.21
Upside: +36.73%
Jul 9, 2024
Initiates: Overweight
Price Target: $44
Current: $35.54
Upside: +23.80%
May 15, 2024
Maintains: Equal-Weight
Price Target: $80 → $40
Current: $10.08
Upside: +296.83%
Nov 13, 2023
Maintains: Equal-Weight
Price Target: $86 → $82
Current: $71.65
Upside: +14.45%
Nov 9, 2023
Maintains: Equal-Weight
Price Target: $8 → $7
Current: $6.32
Upside: +10.76%
Nov 8, 2023
Maintains: Equal-Weight
Price Target: $16 → $17
Current: $16.41
Upside: +3.60%
Oct 24, 2023
Maintains: Equal-Weight
Price Target: $13 → $10
Current: $6.39
Upside: +56.49%
Aug 17, 2023
Initiates: Equal-Weight
Price Target: $16
Current: $7.86
Upside: +103.56%
Aug 3, 2023
Reiterates: Equal-Weight
Price Target: $6
Current: $1.76
Upside: +240.91%
May 10, 2023
Maintains: Overweight
Price Target: $11 → $10
Current: $3.26
Upside: +206.75%
Mar 7, 2023
Reiterates: Equal-Weight
Price Target: $2.75
Current: $0.90
Upside: +205.56%
Feb 27, 2023
Maintains: Equal-Weight
Price Target: $11 → $5
Current: $5.75
Upside: -13.04%
Feb 21, 2023
Maintains: Equal-Weight
Price Target: $11 → $10
Current: $2.31
Upside: +332.90%
Feb 21, 2023
Maintains: Overweight
Price Target: $80 → $73
Current: $31.67
Upside: +130.50%
Aug 4, 2022
Downgrades: Equal-Weight
Price Target: $350 → $250
Current: $185.77
Upside: +34.58%
May 12, 2022
Maintains: Equal-Weight
Price Target: $7 → $5
Current: $1.57
Upside: +218.47%